[Temporary approval for intranasal naloxone: Setting up in a French addiction center].


Intranasal naloxone aims at preventing opioid overdose related deaths in active drug users. In France, it has been available since July 2016 through a temporary approval which requires a hospital-based pharmacy and a nominative registration of each patient. We present the characteristics of the first patients who could receive this prescription in our… (More)
DOI: 10.1016/j.therap.2018.03.003


  • Presentations referencing similar topics